PMOS vs PCOD: Same Condition, Three Different Names

If you have a scan report that says PCOD, a friend who says PCOS and a new article that says PMOS, nothing has gone wrong with your diagnosis. You are looking at three labels from three different decades stuck to the same set of findings.

Where each name came from

The naming problem is older than most of the people arguing about it. Doctors described the condition long before anyone agreed on how to diagnose it, so the vocabulary moved faster than the science.

The sequence, from a 2021 history of the diagnosis published in F&S Science:

1. 1935 — Stein and Leventhal describe a triad of absent periods, polycystic ovaries and signs of excess androgens.
2. 1950s–1980s — the condition is characterised in more detail, but there are no agreed diagnostic criteria. “Polycystic ovarian disease” is one of several terms in circulation.
3. 1990 — a National Institutes of Health conference defines what is now called classic PCOS.
4. 2003 — the Rotterdam consensus widens the definition to any two of three features.
5. 2006 — the Androgen Excess Society issues criteria anchored to long-term metabolic risk.
6. 2026 — a global consensus renames the condition PMOS.

“Disease” was dropped along the way for a specific reason. A disease is one thing happening one way. What Rotterdam described was a cluster of three features that combine into four different patterns — which is a syndrome, not a disease.

The objection is not new either. A 2004 commentary in the International Journal of Fertility and Women’s Medicine called PCOD a misnomer and argued for a different name entirely. That was expert opinion rather than evidence, but it shows the naming argument has been running for more than twenty years.

What changed in 2026

In June 2026, a consensus process involving 56 academic, clinical and patient organisations renamed the condition in The Lancet. The process drew on surveys of 14,360 people with the condition and health professionals across every world region.

The stated problem with the old name was accuracy: “polycystic” implies pathological ovarian cysts that are not cysts, and it hid the endocrine and metabolic half of the condition. The same criticism lands harder on PCOD, which keeps the misleading word and calls a syndrome a disease.

The consensus explicitly chose evolution over transformation — a transition period, with education and health-system alignment, rather than an overnight switch. That is why your records still say one thing and a new journal article says another. The full story is in PCOS is now PMOS.

PMOS vs PCOD, side by side

	PCOD	PCOS	PMOS
Stands for	Polycystic ovarian disease	Polycystic ovary syndrome	Polyendocrine metabolic ovarian syndrome
Status	Informal legacy term; not defined in any current guideline	Official name from 1990 until 2026	Consensus name from June 2026
Where you see it	Clinics, lab reports and media in India and South Asia	Existing records, most research, most of the internet	New guidelines and journals; clinics during the transition
Diagnostic criteria	None of its own — clinicians using it apply Rotterdam	Rotterdam: any two of three features	Rotterdam: any two of three features, unchanged
Treatment it implies	Same	Same	Same
Known problem with the name	Implies cysts, and implies one uniform disease	Implies cysts; omits the metabolic features	Longer, and still unfamiliar to most clinicians

“PCOD is milder than PCOS” — why that is not a real distinction

This is the claim that brings most people to this page, and it does not hold up.

No diagnostic criteria set defines PCOD as a separate, milder entity — not the NIH 1990 criteria, not Rotterdam 2003, not the Androgen Excess Society criteria, and not the 2023 international guideline, which runs to 254 recommendations and practice points and never establishes PCOD as a distinct diagnosis. There is no PCOD blood test and no PCOD threshold. A clinician writing PCOD on a report is using an older word for the condition the guideline calls PMOS.

Severity does vary, sometimes enormously. It just does not vary by which word your clinic prefers.

What actually varies: your phenotype

Rotterdam’s two-of-three rule produces four recognised patterns, labelled A to D. This is the distinction that PCOD-versus-PCOS is a clumsy stand-in for.

Phenotype	High androgens	Irregular or absent ovulation	Polycystic ovaries on scan or raised AMH
A (classic, full)	Yes	Yes	Yes
B (classic, non-polycystic)	Yes	Yes	No
C (ovulatory)	Yes	No	Yes
D (non-hyperandrogenic)	No	Yes	Yes

Phenotype is not a severity score you can read off a label, and the evidence base is not strong enough to promise that one letter predicts your outcome. What it does explain is why two people with the same diagnosis look nothing alike — and why generic advice fits some people badly.

The 2023 guideline’s other change matters here: it strengthened recognition of the metabolic features that sit alongside the reproductive ones, including cardiovascular risk factors and sleep apnoea. Those belong in the conversation whichever of the three names is on your paperwork. If you have not worked out which pattern fits you, start with the four types.

Why PCOD is so common in India specifically

If you are reading this from India, Pakistan or Bangladesh, PCOD is probably the only term you have heard offline. The term stuck in regional clinical usage while international bodies moved to PCOS, and it has been reinforced by two decades of local media.

The population involved is not small. A 2021 systematic review and meta-analysis of 12 studies and 4,473 Indian adolescent girls aged 14–19 found a pooled prevalence of 17.7% by Rotterdam criteria (95% CI 11.8–23.7) — roughly one in five. Read that figure with care: heterogeneity between the studies was very high, and hospital-based samples reported more than community-based ones, which inflates the pooled estimate. It is a signal of scale, not a precise number.

For comparison, the 2026 consensus paper describes the condition as affecting about one in eight women globally.

If your report says PCOD, what should you ask?

Three questions get you further than any relabelling:

1. Which of the three features do I actually have? High androgens, irregular ovulation, polycystic ovarian morphology or raised AMH — you need at least two, and knowing which two gives you your phenotype.
2. Was anything else ruled out first? Thyroid disease, raised prolactin and non-classic congenital adrenal hyperplasia can mimic the picture and are excluded before diagnosis.
3. What are we monitoring, and how often? This is the part the name has never determined.

The mechanics of each criterion, including the AMH thresholds and the stricter bar for adolescents, are set out in the PMOS diagnosis criteria.

Which word should you use?

Use whatever gets you understood. In an Indian clinic, PCOD will be understood instantly and PMOS may not be. In a new referral letter, “PMOS (previously PCOS)” is the phrasing that works during the transition. When searching for research, PCOS still returns the most material by a wide margin, because thirty-six years of literature is filed under it.

None of these is wrong. Only one is current. If you want a script for raising the new name without it becoming an argument, there is one in telling your doctor about PMOS.

Your next step

Find your last scan report or clinic letter and highlight which of the three features are actually documented in it. Not the heading — the findings. That tells you your phenotype, which is the thing worth knowing, and it takes about five minutes. The rest of the diagnosis section starts from there.